Medtronic touts VenaSeal data

Medtronic (NYSE:MDT) today released clinical data from a study of its VenaSeal closure system, claiming consistent long-term durability and improved quality of life in patients with venous reflux disease treated with the system The VenaSeal system from the Fridley, Minn.-based medical giant uses a proprietary medical adhesive to close superficial veins in lower extremities in patients with symptomatic venous reflux, or varicose veins. To administer the adhesive, an operating physician inserts a catheter through an access site in the leg and guides it, with ultrasound, into diseased veins to administer the VenaSeal adhesive. Along with manual compression, the physician closes the vein so blood is rerouted through other healthy veins in the leg, Medtronic said. “As shown by our unmatched body of Level 1 evidence in the venous industry, Medtronic has demonstrated its deep-rooted commitment to providing clinically-proven and patient friendly treatment options for patients with chronic venous insufficiency. We’re enthusiastic about the unveiling of such strong datasets, and we look forward to continuing to build upon this clinical program,” endoVenous biz GM Sandra Lesenfants said in a press release. The data comes from the VeClose pivotal clinical study and 2 subanalysis, as well as 3-year results from the eScope study, Medtronic said. The data was presented at the 2016 Charing Cross Symposium in London. Data from the VeClose trial indicated long term non-infer...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Vascular Medtronic Source Type: news